Novavax postpones US trial of COVID-19 vaccine candidate to November


A handful of companies have started testing their vaccines in late stage trials (pictured)

Novavax Inc on Tuesday delayed the start of an advanced stage US trial of its investigational coronavirus vaccine by about a month until the end of November, citing delays in ramping up the manufacturing process.

The US-based drug developer said data from a separate Phase 3 trial underway in Britain is expected by the first quarter of 2021 and could serve as the basis for regulatory approval, making climb its shares by 3.4% at the start of the session.

Data from an early to mid-stage or Phase 2 vaccine trial is now due on Friday, the company said. The first data had shown that the vaccine produced high levels of antibodies against the new coronavirus.

A handful of companies, including bigger rivals Pfizer Inc and AstraZeneca Plc, have started testing their vaccines in late trials, though none of them have yet obtained regulatory approvals.

Novavax announced in August that it would deliver 60 million doses of its coronavirus vaccine candidate to the UK as of the first quarter of 2021.

The company is also preparing to deliver 100 million doses to the United States by January after receiving $ 1.6 billion for its potential vaccine and has also signed supply agreements with Canada and Japan.

(This story was not edited by GalacticGaming staff and is auto-generated from a syndicated feed.)


Please enter your comment!
Please enter your name here